Ten-year fracture risk tools and comprehensive hormone assessments help clinicians evaluate bone density and direct skeletal care in hypogonadal men.
You visit your doctor after months of low energy, joint stiffness, and declining physical stamina. Routine blood tests reveal a total testosterone level sitting just below the standard reference range. During the consultation, your physician mentions that low hormone levels can also weaken your skeleton. You are left wondering if starting testosterone replacement therapy will protect your bones, or if bone density and fracture risk require an entirely different approach.
This guide provides a comprehensive breakdown of the relationship between male sex hormones, bone mineral density, and clinical fracture outcomes. It examines the cellular pathways of bone remodeling, outlines standard diagnostic procedures, and reviews major clinical trials. Understanding these distinctions helps you have a more informed, productive discussion with your healthcare provider.
This article is for educational and informational purposes only. It does not constitute personal medical advice, diagnosis, or treatment recommendations. Always consult a qualified physician or endocrinologist before starting, changing, or discontinuing any hormonal therapy or bone-directed medication.
Understanding how hormones influence skeletal strength requires separating laboratory measurements from real-world clinical outcomes. The following points summarize current medical knowledge:
Bone is a dynamic living tissue that undergoes constant remodeling. Old, damaged bone is systematically removed, while new mineralized matrix is laid down in its place. This continuous cycle depends on a balance between two primary cell types: osteoclasts, which resorb bone, and osteoblasts, which form new bone tissue.
Sex steroids are among the most important regulators of this remodeling balance. In men, both androgens and estrogens are required to maintain skeletal integrity across the lifespan. Learning about hormonal function and fundamentals helps clarify how these chemical messengers preserve the structural framework of the body.
Testosterone exerts direct effects on the skeleton by binding to androgen receptors located on osteoblasts, osteocytes, and osteoclasts. When testosterone binds to androgen receptors on osteoblasts, it stimulates cellular proliferation and differentiation. This signaling pathway promotes the synthesis of type I collagen, osteocalcin, and other matrix proteins that form the scaffolding for new bone mineral.
Androgen receptor activation also influences the lifespan of bone cells. It prolongs the survival of osteoblasts and osteocytes while promoting the programmed death of bone-resorbing osteoclasts. Through these direct mechanisms, adequate circulating testosterone helps sustain bone formation and prevents excessive bone breakdown.
Although testosterone is the primary circulating androgen in men, it is not the sole driver of male bone density. A significant portion of testosterone's skeletal benefit occurs through its conversion into estradiol by the aromatase enzyme. This conversion takes place in adipose tissue, testicular Leydig cells, and within bone tissue itself.
Clinical research demonstrates that circulating estradiol concentrations correlate more strongly with male bone mineral density and bone turnover markers than testosterone concentrations do. Men with rare genetic mutations that disable the aromatase enzyme or the estrogen receptor develop severe osteoporosis and continuous bone loss. They exhibit these skeletal deficits despite having normal or elevated circulating testosterone levels.
Estradiol is especially vital for slowing bone resorption. It reduces the production of pro-inflammatory cytokines that stimulate osteoclast activity and modulates the RANKL and osteoprotegerin pathway. Without sufficient estradiol, osteoclasts remove bone faster than osteoblasts can replace it, leading to structural micro-damage and thinning trabecular networks.
The male skeleton contains two distinct structural compartments. Cortical bone is the dense, solid outer shell that forms the shafts of long bones, providing mechanical resistance to bending and torsion. Trabecular bone is the internal, spongy lattice found within the vertebrae, pelvis, and the ends of long bones.
Trabecular bone has a much higher surface area per unit of volume than cortical bone. As a result, it is far more sensitive to hormonal fluctuations and metabolic changes. When sex steroid levels fall, trabecular bone exhibits rapid thinning and perforation of its structural plates. Cortical bone loss occurs more gradually through increased intracortical porosity and endosteal resorption. Over time, these combined losses reduce the overall load-bearing capacity of the skeleton.
To understand how hormone therapy affects the skeleton, it is necessary to distinguish between imaging measurements, structural engineering properties, and clinical outcomes. These terms are related, but they are not interchangeable.
Areal bone mineral density is the most common metric used in clinical practice. It is measured using dual-energy X-ray absorptiometry, commonly known as a DXA scan. DXA calculates the mineral content within a two-dimensional projection area of bone, expressing the result in grams per square centimeter.
While areal density is a valuable diagnostic tool, it has inherent technical limitations. Because it is a two-dimensional measurement, it does not fully capture the three-dimensional geometry or true volumetric density of the bone. Larger bones can appear to have higher areal density simply due to their physical dimensions. Areal measurements also cannot distinguish between changes occurring in the trabecular core and the cortical shell.
Volumetric bone mineral density measures true three-dimensional mass per unit volume. This measurement is obtained using quantitative computed tomography or high-resolution peripheral quantitative computed tomography. These advanced imaging techniques separate cortical and trabecular compartments, measuring the thickness and spacing of individual trabeculae.
Using volumetric imaging data, researchers can apply finite element analysis. This computational technique treats the bone as an engineering structure, applying simulated loads to calculate estimated failure load and bone strength. While estimated bone strength provides deep insight into skeletal mechanics, it remains a surrogate endpoint rather than a direct measure of clinical fractures.
A clinical fracture is an actual broken bone that causes pain, functional impairment, and requires medical intervention. The primary goal of any skeletal health strategy is to prevent clinical fractures, especially fragility fractures resulting from low-energy trauma, such as a fall from standing height.
Fracture risk is determined by many factors beyond bone density alone. A person's age, balance, muscle strength, gait speed, vision, and cognitive status all influence their likelihood of falling. The geometry of the hip, the quality of collagen within the bone matrix, and the presence of underlying chronic diseases also play major roles. Consequently, an intervention that improves bone density on a scan will not necessarily prevent a person from suffering a broken bone if fall risks and mechanical impacts remain high.
Osteoporosis in men is frequently underdiagnosed and undertreated. Because bone loss occurs without outward symptoms, many men only learn of their skeletal vulnerability after sustaining a painful fracture. A structured evaluation helps identify men who require clinical intervention before a major injury occurs.
Clinical practice guidelines from major medical organizations outline specific criteria for skeletal evaluation in men. The Endocrine Society recommends bone mineral density testing for all men aged 70 and older, regardless of other clinical factors. Testing is also recommended for men aged 50 to 69 who have specific risk factors for accelerated bone loss or fractures.
Key risk factors that warrant early screening include:
A central DXA scan of the lumbar spine, total hip, and femoral neck is the standard diagnostic test for male osteoporosis. The scan generates two distinct statistical scores: the T-score and the Z-score.
The T-score compares the patient's bone mineral density to that of a healthy young adult reference population. The World Health Organization defines these diagnostic categories:
The Z-score compares the patient's bone density to an age-matched and sex-matched reference group. In men under the age of 50, diagnostic categories rely on Z-scores rather than T-scores. A Z-score of -2.0 or lower is classified as bone mineral density below the expected range for age. It strongly suggests the presence of an underlying secondary cause of bone loss that requires thorough medical investigation.
A DXA scan provides useful structural data, but it does not capture the full clinical picture. To bridge this gap, clinicians utilize the Fracture Risk Assessment Tool, known as FRAX. Developed by the World Health Organization, FRAX calculates a patient's 10-year probability of suffering a major osteoporotic fracture (clinical spine, forearm, hip, or shoulder) and a 10-year probability of a hip fracture.
The FRAX calculator integrates multiple clinical risk factors alongside or in place of femoral neck bone mineral density:
Medical guidelines generally recommend pharmacologic treatment when the 10-year probability of a major osteoporotic fracture reaches 20% or higher, or when the 10-year probability of a hip fracture reaches 3% or higher.
Unlike postmenopausal osteoporosis in women, which is primarily driven by age-related ovarian hormone cessation, male osteoporosis is caused by secondary factors in up to 50% of cases. Identifying and addressing these underlying contributors is critical before selecting a treatment plan.
A comprehensive laboratory workup for a man with low bone density or an unexpected fracture typically includes:
Men experiencing unexplained bone loss can review signs, causes, and risk factors of low testosterone to see how hormonal health fits into their broader diagnostic profile.
Interpreting laboratory tests requires an understanding of how distinct biomarkers interact. Hormones and metabolic markers should always be evaluated in context rather than as isolated numbers.
Total testosterone measures the sum of all circulating testosterone in the bloodstream, including protein-bound and unbound fractions. Because testosterone production follows a circadian rhythm, blood samples must be drawn in the early morning while fasting.
Clinical guidelines generally recognize a total testosterone threshold near 300 ng/dL (10.4 nmol/L) as a benchmark for potential deficiency. A diagnosis of hypogonadism requires at least two separate, early-morning fasting measurements falling below this range, accompanied by consistent clinical symptoms. An isolated low reading on a single test is insufficient to establish a chronic hormonal disorder.
In the circulation, approximately 60% of testosterone is bound tightly to sex hormone-binding globulin (SHBG), while about 38% is bound loosely to albumin. The remaining 1% to 2% circulates freely. Free testosterone and albumin-bound testosterone together make up bioavailable testosterone, which is readily accessible to target tissues, including bone.
SHBG concentrations rise naturally with age and are altered by conditions such as liver disease, thyroid dysfunction, obesity, and insulin resistance. In men with altered SHBG levels, total testosterone can be misleadingly normal or low. Measuring free testosterone, either by equilibrium dialysis or by calculation using total testosterone, SHBG, and albumin, provides an accurate reflection of active circulating hormone levels.
Serum estradiol is critical for maintaining male skeletal integrity. Because circulating estradiol levels in men are relatively low compared to premenopausal women, standard direct immunoassay methods can lack analytical precision at low concentrations.
When evaluating complex bone loss or hormonal imbalances, liquid chromatography-tandem mass spectrometry is the preferred assay method. Men with persistently low bioavailable estradiol levels face a significantly higher risk of accelerated bone loss and subsequent fragility fractures.
Pituitary gonadotropins, specifically luteinizing hormone (LH) and follicle-stimulating hormone (FSH), differentiate between primary and secondary hypogonadism.
In primary hypogonadism, testicular failure leads to low testosterone levels alongside elevated LH and FSH concentrations, as the pituitary attempts to stimulate non-responsive Leydig cells. In secondary hypogonadism, pituitary or hypothalamic dysfunction results in low or inappropriately normal gonadotropin levels despite low circulating testosterone. Identifying the root cause is essential for selecting appropriate medical interventions.
Vitamin D is a fat-soluble secosteroid essential for intestinal calcium absorption and bone mineralization. A 25-hydroxyvitamin D blood test reflects total body storage from sunlight exposure and dietary intake. Levels below 20 ng/mL (50 nmol/L) are classified as deficient and can trigger secondary hyperparathyroidism, which strips calcium from bone tissue.
Bone turnover markers, such as serum C-terminal telopeptide of type I collagen (a marker of bone resorption) and procollagen type I N-propeptide (a marker of bone formation), measure active remodeling rates. While they are not used to diagnose osteoporosis, they help clinicians monitor skeletal response to anti-resorptive or anabolic osteoporosis therapies.
For a deeper look into testing procedures, readers can consult our guide to testosterone testing and biomarkers.
Over the past three decades, numerous clinical studies have examined whether restoring testosterone to normal physiological levels improves bone density and skeletal structure in men.
The Testosterone Trials (T-Trials) were a coordinated set of double-blind, placebo-controlled clinical trials designed to evaluate the efficacy of testosterone therapy in older men with symptomatic hypogonadism. The T-Trials Bone Study specifically investigated changes in volumetric bone mineral density and estimated bone strength.
The study enrolled men aged 65 and older with an average baseline total testosterone level below 275 ng/dL. Participants were randomized to receive either daily testosterone gel adjusted to maintain physiological levels or a matching placebo gel for one year. Outcomes were evaluated using quantitative computed tomography at baseline and at 12 months.
The results demonstrated clear structural improvements in the testosterone-treated group:
These findings confirmed that physiological testosterone replacement exerts a positive biological effect on bone mineral accretion and three-dimensional trabecular architecture in older men with low testosterone levels.
The findings from the T-Trials Bone Study and similar short-term investigations established that testosterone improves volumetric density and calculated strength. However, these studies were not designed or powered to assess clinical fractures.
In pharmacology, an improvement in a surrogate marker (such as a DXA measurement or CT scan) does not guarantee an improvement in the hard clinical outcome of interest (such as a reduction in broken bones). Bone density accounts for only a portion of overall bone strength. It provides no information about how an intervention affects fall frequency, reaction times, balance, or physical risk-taking behaviors, all of which directly dictate fracture incidence.
To determine whether testosterone replacement therapy actually reduces the occurrence of broken bones in everyday life, researchers required a large-scale, long-term clinical trial tracking real-world fracture events.
The TRAVERSE study was a multicenter, randomized, double-blind, placebo-controlled trial designed primarily to assess the cardiovascular safety of testosterone replacement therapy. Within this trial, a pre-specified fracture sub-study evaluated the incidence of clinical fractures over an extended follow-up period.
The study enrolled 5,204 men aged 45 to 80 years. To participate, men had to meet strict entry criteria:
Participants were randomly assigned to apply a daily transdermal 1.62% testosterone gel (with doses adjusted to maintain levels between 350 and 750 ng/dL) or a matching placebo gel. The median duration of treatment was 22 months, and the median overall follow-up period was 3.19 years.
Importantly, osteoporosis was not a required entry criterion for the TRAVERSE trial. Baseline bone mineral density was not measured, and participants were not selected based on previous fracture history.
Contrary to the long-standing assumption that higher bone mineral density from testosterone therapy would reduce broken bones, the TRAVERSE trial found no protective effect against fractures.
Over the median follow-up of 3.19 years, clinical fractures occurred in:
Statistical analysis revealed a hazard ratio of 1.43 (95% confidence interval, 1.04 to 1.97) for clinical fractures in the testosterone group compared to the placebo group. Clinical fractures were numerically and statistically more frequent among men receiving testosterone therapy.
The types of fractures observed were consistent across both groups, with the most common fracture sites being the ribs, wrists, and ankles. Most fractures were associated with minor trauma, primarily falls from standing height.
The findings from the TRAVERSE trial generated significant discussion among endocrinologists and bone health specialists. Several important clinical considerations help put these findings into perspective:
Readers interested in the latest clinical trials can review the broader evidence base surrounding testosterone replacement therapy and emerging research.
The disconnect between bone density improvements and clinical fracture outcomes requires a clear, practical approach to managing skeletal health in men with low hormone levels.
Testosterone replacement therapy is approved and indicated for the treatment of biochemically confirmed, symptomatic hypogonadism. Its primary clinical goals are to alleviate symptoms such as low sexual desire, erectile dysfunction, decreased muscle mass, and chronic fatigue, while restoring physiological hormone concentrations.
Testosterone therapy is not approved as a primary treatment for male osteoporosis, nor should it be prescribed solely to prevent bone fractures. When a man is diagnosed with both hypogonadism and osteoporosis, these conditions must be managed as related but distinct clinical entities.
When a man meets clinical criteria for osteoporosis or demonstrates a high 10-year fracture risk on a FRAX assessment, guideline-directed anti-osteoporosis medications are the standard of care. These medications have established efficacy in large-scale randomized trials, with proven capability to reduce vertebral, non-vertebral, and hip fractures.
Primary pharmacologic options for male osteoporosis include:
Current endocrine guidelines state that a man with high fracture risk and hypogonadism should usually receive an established anti-osteoporosis medication, regardless of whether he also starts testosterone therapy for his hormone deficiency.
Pharmacologic therapies must be supported by foundational lifestyle measures that preserve bone structure and reduce the likelihood of falls.
Essential non-pharmacologic strategies include:
The relationship between testosterone, bone mineral density, and fracture risk varies depending on an individual's complete medical history. The following illustrative models show how clinicians approach different presentations.
An asymptomatic 52-year-old man undergoes broad routine blood testing, revealing a total testosterone of 270 ng/dL. A repeat morning fasting test confirms a level of 280 ng/dL. He has no history of broken bones, maintains an active lifestyle, and does not experience low libido or fatigue.
Clinical Approach: Because hypogonadism requires both compatible clinical symptoms and consistently low hormone levels, automatic testosterone therapy is not indicated. The clinician evaluates his overall health, checking for reversible factors like poor sleep, weight gain, or chronic stress. A bone density scan is not immediately indicated based on his age alone, unless other major clinical risk factors, such as long-term steroid use, are identified.
A 48-year-old man presents with persistent sexual dysfunction, decreased muscle mass, and severe fatigue. Two morning fasting lab tests show total testosterone concentrations of 190 ng/dL and 210 ng/dL, with low LH and FSH levels. Because of chronic back pain, his doctor orders a spine X-ray and a subsequent DXA scan, which reveals a lumbar spine T-score of -2.6 (osteoporosis).
Clinical Approach: The patient has a confirmed diagnosis of secondary hypogonadism and meets diagnostic criteria for osteoporosis. The clinician initiates testosterone replacement therapy to address his systemic hypogonadal symptoms and hormonal deficit. Because his T-score is below -2.5, the clinician also evaluates him for secondary causes of bone loss and discusses starting an established anti-osteoporosis medication, such as an oral bisphosphonate, to ensure proven fracture protection.
A 74-year-old man slips on a wet sidewalk and sustains a non-displaced fracture of his proximal femur (hip). Subsequent blood testing during follow-up shows a total testosterone level of 240 ng/dL and a 25-hydroxyvitamin D level of 16 ng/mL. A DXA scan shows a total hip T-score of -2.7.
Clinical Approach: A hip fracture resulting from a fall from standing height in a man over 50 is a defining event for osteoporosis, regardless of the baseline T-score. Guideline-directed care prioritizes immediate bone-specific therapy, such as zoledronic acid or denosumab, alongside vitamin D repletion and fall-prevention physical therapy. The low testosterone is investigated as a potential contributing secondary factor. However, starting testosterone therapy alone is not considered adequate management for his severe fracture risk.
A 68-year-old man begins androgen deprivation therapy using a gonadotropin-releasing hormone agonist as part of his medical treatment for localized prostate cancer. This treatment intentionally suppresses his serum testosterone to castrate levels (below 20 ng/dL) to halt cancer progression.
Clinical Approach: Profound, therapeutic androgen suppression causes rapid bone loss and substantially elevates 10-year fracture risk. In this scenario, testosterone therapy is strictly contraindicated. Instead, the oncology and endocrine teams perform baseline DXA screening and proactively initiate anti-resorptive medications (such as denosumab or alendronate) to preserve bone mineral density and prevent treatment-induced fractures.
Readers navigating these issues can learn more by exploring our section on low testosterone.
Navigating bone health and hormonal therapies requires personalized guidance from a medical specialist. Bringing specific questions to your consultation helps ensure all clinical angles are thoroughly evaluated.
You can read more about clinical consultations and research methodologies on our about page.
Revisiting this guide is recommended whenever you receive new DXA scan results, experience changes in your circulating hormone levels, or undergo an evaluation following an unexpected broken bone.
Maintaining lifelong skeletal strength requires an accurate diagnosis, an understanding of clinical trial evidence, and a balanced management plan tailored to your specific bone density and fracture risk.
Testostra explains testosterone biology, testing, symptoms, lifestyle factors and TRT with careful sourcing and clear clinical limits.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra
